Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Open Access
- 1 August 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (8), 4856-4860
- https://doi.org/10.1128/aac.00843-15
Abstract
Multidrug-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are endemic to hospitals in New York City and other regions. RPX7009 is a novel β-lactamase inhibitor with activity against serine carbapenemases. We tested the activity of meropenem plus RPX7009 against 4,500 recent Gram-negative clinical isolates from 11 New York City hospitals. The meropenem-RPX7009 combination was found to have excellent in vitro activity against Escherichia coli , K. pneumoniae , and Enterobacter spp., including multidrug-resistant (MDR) KPC-producing strains. Overall, 131/133 (98.5%) KPC-producing Enterobacteriaceae strains were inhibited by meropenem (≤1 μg/ml) plus RPX7009 (8 μg/ml). In a limited number of strains, the combination appeared to have reduced activity against KPC-producing K. pneumoniae isolates with diminished ompK35 and ompK36 expression. The addition of RPX7009 did not affect the activity of meropenem against Acinetobacter baumannii and Pseudomonas aeruginosa . The meropenem-RPX7009 combination shows promise as a novel agent against KPC-producing Enterobacteriaceae and deserves further study. Other approaches will be needed to address multidrug-resistant A. baumannii and P. aeruginosa , which typically possess different mechanisms of carbapenem resistance.Keywords
This publication has 16 references indexed in Scilit:
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine CarbapenemasesPublished by American Chemical Society (ACS) ,2015
- β-Lactam/β-Lactamase Inhibitor CombinationsAnnals of Pharmacotherapy, 2014
- Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countriesJournal of Antimicrobial Chemotherapy, 2014
- Carbapenem-Resistant Enterobacteriaceae: An Emerging Problem in ChildrenClinical Infectious Diseases, 2012
- Characterization of -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)Journal of Antimicrobial Chemotherapy, 2012
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006
- Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.International Journal of Antimicrobial Agents, 2006
- Emergence of Carbapenem-Resistant Klebsiella Species Possessing the Class A Carbapenem-Hydrolyzing KPC-2 and Inhibitor-Resistant TEM-30 -Lactamases in New York CityClinical Infectious Diseases, 2004
- Emergence of Oxacillinase-Mediated Resistance to Imipenem inKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2004
- Emerging carbapenemases in Gram-negative aerobesClinical Microbiology & Infection, 2002